Free Trial
NASDAQ:AIMD

Ainos Q4 2025 Earnings Report

Ainos logo
$1.23 -0.06 (-4.65%)
Closing price 03:58 PM Eastern
Extended Trading
$1.24 +0.01 (+0.81%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ainos EPS Results

Actual EPS
-$0.85
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Ainos Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ainos Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
Monday, March 30, 2026
Conference Call Time
7:00AM ET

Ainos Earnings Headlines

Financial Analysis: Ainos (NASDAQ:AIMD) versus Everpure (NYSE:P)
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
See More Ainos Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ainos? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ainos and other key companies, straight to your email.

About Ainos

Ainos (NASDAQ:AIMD) (NASDAQ: AIMD) is a healthcare technology company developing solutions in artificial intelligence, point-of-care testing and telehealth. The company focuses on technologies intended to support non-invasive disease screening, decentralized healthcare delivery and improved access to diagnostic services.

Ainos’ AI Nose platform uses artificial intelligence and analysis of volatile organic compounds to identify patterns that may be associated with certain health conditions. The company is also developing point-of-care testing products and related diagnostic applications designed for use outside traditional laboratory settings.

In addition, Ainos has worked on telehealth solutions and therapeutic products, including its VELDONA low-dose interferon-alpha platform. The company’s activities and product development efforts are focused primarily on healthcare applications in the United States and Asia-Pacific markets.

View Ainos Profile